IL17A and myeloid sarcoma: reported that healthy control or autologous neurons cultured with iPSCs-derived reactive astrocytes from benign MS patients [an Expanded Disability Status Scale (EDSS) score <3 with full earning ability and a disease duration of over 15 years] exhibit less axonal damage than astrocytes from healthy controls and progressive MS patients [a rapid disability accumulation (EDSS > 6) within 15 years of disease duration] after treatment with TNF-α combined with IL-17A (44).